The global tendonitis treatment market was valued at USD 207.14 billion in 2022 and it is predicted to surpass around USD 300.20 billion by 2032 with a CAGR of 3.78% from 2023 to 2032.
Key Pointers
Report Coverage | Details |
Market Size in 2022 | USD 207.14 billion |
Revenue Forecast by 2032 | USD 300.20 billion |
Growth rate from 2023 to 2032 | CAGR of 3.78% |
Base Year | 2022 |
Forecast Period | 2023 to 2032 |
Regions Covered | North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
Companies Covered | Merck and Co. Inc.; Bayer AG; AstraZeneca; Boehringer Ingelheim Pharmaceuticals, Inc.; Abbott; Pfizer; GlaxoSmithKline PLC; Almatica Pharma, Inc. |
A growing aging population and sports & occupational work injuries & sudden injuries caused due to trauma or physical work are some of the factors that cause tendonitis, thereby contributing to the industry growth. Adolescents are becoming susceptible to arm-, wrist-, and hand-related injuries owing to the increasing usage of electronic devices, thereby, making them more prone to developing tendonitis. The growing prevalence of bone disorders, osteoarthritis, rheumatoid arthritis, and osteoporosis makes the geriatric population group susceptible to tendonitis.
Annually, over 70,000 U.S. individuals suffering from tendonitis miss their work, as per the Bureau of Labor Statistics. As per the WHO estimates in 2021, approximately 1.71 billion individuals globally are affected by musculoskeletal conditions and are prone to tendonitis. The increasing incidence of sports-related injuries due to the increased sports activities is contributing to the market growth. The adoption of healthy habits is increasing with people across the world taking up at least some physical activity regularly, this is anticipated to increase the incidence of sports injuries thereby contributing to the industry growth. Sports injuries make up 12% of the total injuries that are reported at hospitals in the U.S., most of which are tendon-related injuries.
According to a study published by sports medicine professors from Duke University and the University of Virginia, approximately 40 to 50% of competitive runners have suffered from Achilles tendinopathy. The growing incidence of tendonitis in the general population, which accounts for 5 to 10 cases per 100,000 people is attributed to an increase in the market demand during the forecast period. Various treatment options, such as OTC drugs, surgeries, and physical therapy have increased the number of individuals undergoing treatments, which will encourage the industry's growth. Physical therapy is one of the first lines of treatment for people with chronic tendon conditions as it helps in eccentric strengthening and is effective to treat chronic tendon conditions.
According to the international journal of physiotherapy, physical therapy is efficient to treat lower limb and upper limb tendinopathies, and these factors are attributed to an increase in the demand for the market during the forecast period. Tendons are highly aligned connective tissues that help transmit force from muscles to bones, hence these tissues are at a higher risk to get injured; over 32 million tendon-related injuries are reported every year, and tendinopathies are 50% of the injuries reported in sports players, and athletes. Sudden injuries, prolonged inactivity, and treatment-associated side effects are attributed to drive the industry during the forecast period.
Tendonitis Treatment Market Segmentations:
By Treatment
By Condition
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Tendonitis Treatment Market
5.1. COVID-19 Landscape: Tendonitis Treatment Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Tendonitis Treatment Market, By Treatment
8.1. Tendonitis Treatment Market, by Treatment, 2023-2032
8.1.1. Therapy
8.1.1.1. Market Revenue and Forecast (2019-2032)
8.1.2. Surgery
8.1.2.1. Market Revenue and Forecast (2019-2032)
Chapter 9. Global Tendonitis Treatment Market, By Condition
9.1. Tendonitis Treatment Market, by Condition, 2023-2032
9.1.1. Tennis Elbow
9.1.1.1. Market Revenue and Forecast (2019-2032)
9.1.2. Golfer’s Elbow
9.1.2.1. Market Revenue and Forecast (2019-2032)
9.1.3. Pitcher’s Elbow
9.1.3.1. Market Revenue and Forecast (2019-2032)
9.1.4. Jumper’s Knee
9.1.4.1. Market Revenue and Forecast (2019-2032)
9.1.5. Swimmer’s Shoulder
9.1.5.1. Market Revenue and Forecast (2019-2032)
9.1.6. Achilles Tendonitis
9.1.6.1. Market Revenue and Forecast (2019-2032)
Chapter 10. Global Tendonitis Treatment Market, Regional Estimates and Trend Forecast
10.1. North America
10.1.1. Market Revenue and Forecast, by Treatment (2019-2032)
10.1.2. Market Revenue and Forecast, by Condition (2019-2032)
10.1.3. U.S.
10.1.3.1. Market Revenue and Forecast, by Treatment (2019-2032)
10.1.3.2. Market Revenue and Forecast, by Condition (2019-2032)
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Forecast, by Treatment (2019-2032)
10.1.4.2. Market Revenue and Forecast, by Condition (2019-2032)
10.2. Europe
10.2.1. Market Revenue and Forecast, by Treatment (2019-2032)
10.2.2. Market Revenue and Forecast, by Condition (2019-2032)
10.2.3. UK
10.2.3.1. Market Revenue and Forecast, by Treatment (2019-2032)
10.2.3.2. Market Revenue and Forecast, by Condition (2019-2032)
10.2.4. Germany
10.2.4.1. Market Revenue and Forecast, by Treatment (2019-2032)
10.2.4.2. Market Revenue and Forecast, by Condition (2019-2032)
10.2.5. France
10.2.5.1. Market Revenue and Forecast, by Treatment (2019-2032)
10.2.5.2. Market Revenue and Forecast, by Condition (2019-2032)
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Forecast, by Treatment (2019-2032)
10.2.6.2. Market Revenue and Forecast, by Condition (2019-2032)
10.3. APAC
10.3.1. Market Revenue and Forecast, by Treatment (2019-2032)
10.3.2. Market Revenue and Forecast, by Condition (2019-2032)
10.3.3. India
10.3.3.1. Market Revenue and Forecast, by Treatment (2019-2032)
10.3.3.2. Market Revenue and Forecast, by Condition (2019-2032)
10.3.4. China
10.3.4.1. Market Revenue and Forecast, by Treatment (2019-2032)
10.3.4.2. Market Revenue and Forecast, by Condition (2019-2032)
10.3.5. Japan
10.3.5.1. Market Revenue and Forecast, by Treatment (2019-2032)
10.3.5.2. Market Revenue and Forecast, by Condition (2019-2032)
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Forecast, by Treatment (2019-2032)
10.3.6.2. Market Revenue and Forecast, by Condition (2019-2032)
10.4. MEA
10.4.1. Market Revenue and Forecast, by Treatment (2019-2032)
10.4.2. Market Revenue and Forecast, by Condition (2019-2032)
10.4.3. GCC
10.4.3.1. Market Revenue and Forecast, by Treatment (2019-2032)
10.4.3.2. Market Revenue and Forecast, by Condition (2019-2032)
10.4.4. North Africa
10.4.4.1. Market Revenue and Forecast, by Treatment (2019-2032)
10.4.4.2. Market Revenue and Forecast, by Condition (2019-2032)
10.4.5. South Africa
10.4.5.1. Market Revenue and Forecast, by Treatment (2019-2032)
10.4.5.2. Market Revenue and Forecast, by Condition (2019-2032)
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Forecast, by Treatment (2019-2032)
10.4.6.2. Market Revenue and Forecast, by Condition (2019-2032)
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Treatment (2019-2032)
10.5.2. Market Revenue and Forecast, by Condition (2019-2032)
10.5.3. Brazil
10.5.3.1. Market Revenue and Forecast, by Treatment (2019-2032)
10.5.3.2. Market Revenue and Forecast, by Condition (2019-2032)
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Forecast, by Treatment (2019-2032)
10.5.4.2. Market Revenue and Forecast, by Condition (2019-2032)
Chapter 11. Company Profiles
11.1. Merck and Co. Inc.
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Bayer AG
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. AstraZeneca
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Boehringer Ingelheim Pharmaceuticals, Inc.
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. LTE Scientific
11.5. Abbott
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Pfizer
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. GlaxoSmithKline PLC
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Almatica Pharma, Inc.
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
Chapter 12. Research Methodology
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
Chapter 13. Appendix
13.1. About Us
13.2. Glossary of Terms